

Laura Sepp-Lorenzino

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3306261/laura-sepp-lorenzino-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

3,469

citations

32

h-index

58

g-index

68

ext. papers

4,010

ext. citations

6.9

avg, IF

4.65

L-index

#	Paper	IF	Citations
62	Total Synthesis of Spirotryprostatin A, Leading to the Discovery of Some Biologically Promising Analogues. <i>Journal of the American Chemical Society</i> , 1999 , 121, 2147-2155	16.4	388
61	Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. <i>Journal of Biological Chemistry</i> , 2007 , 282, 32582-90	5.4	278
60	A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. <i>Chemistry and Biology</i> , 2001 , 8, 289-99		245
59	Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. <i>Cancer Cell</i> , 2005 , 8, 49-59	24.3	241
58	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. <i>New England Journal of Medicine</i> , 2021 , 385, 493-502	59.2	180
57	Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. <i>Journal of Biological Chemistry</i> , 1995 , 270, 16580-7	5.4	149
56	Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. <i>Molecular Therapy</i> , 2010 , 18, 171-80	11.7	134
55	Structure and function of the insulin-like growth factor I receptor. <i>Breast Cancer Research and Treatment</i> , 1998 , 47, 235-53	4.4	102
54	Synthesis and evaluation of geldanamycin-estradiol hybrids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999 , 9, 1233-8	2.9	89
53	A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. <i>Journal of Biological Chemistry</i> , 1998 , 273, 20243-51	5.4	87
52	A Concise Total Synthesis of Dysidiolide through Application of a Dioxolenium-Mediated Diels-Alder Reaction. <i>Journal of the American Chemical Society</i> , 1998 , 120, 1615-1616	16.4	74
51	Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery. <i>Journal of Histochemistry and Cytochemistry</i> , 2011 , 59, 727-40	3.4	73
50	5T(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAC Conjugates. <i>ChemBioChem</i> , 2016 , 17, 985-9	3.8	73
49	Total Synthesis of Tryprostatin B: Generation of a Nucleophilic Prenylating Species from a Prenylstannane. <i>Journal of the American Chemical Society</i> , 1996 , 118, 12463-12464	16.4	71
48	Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009 , 19, 1240-4	2.9	65
47	Synthesis and evaluation of geldanamycin-testosterone hybrids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000 , 10, 1303-6	2.9	65
46	Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. <i>Journal of Histochemistry and Cytochemistry</i> , 2013 , 61, 901-9	3.4	61

45	An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. <i>Cancer Biology and Therapy</i> , 2010 , 9, 493-503	4.6	56
44	Quantitative evaluation of siRNA delivery in vivo. <i>Rna</i> , 2010 , 16, 2553-63	5.8	54
43	Effective siRNA delivery and target mRNA degradation using an amphipathic peptide to facilitate pH-dependent endosomal escape. <i>Biochemical Journal</i> , 2011 , 435, 475-87	3.8	52
42	An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. <i>Molecular and Cellular Biology</i> , 2007 , 27, 689-98	4.8	52
41	Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 6363-72	8.3	51
40	Analysis of lipid nanoparticles by Cryo-EM for characterizing siRNA delivery vehicles. <i>International Journal of Pharmaceutics</i> , 2011 , 403, 237-44	6.5	49
39	LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001 , 11, 909-13	2.9	47
38	Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. <i>Molecular Therapy</i> , 2010 , 18, 1657-66	11.7	45
37	Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses. <i>Molecular Therapy</i> , 2011 , 19, 567-75	11.7	42
36	3-(Indol-2-yl)indazoles as Chk1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006 , 16, 6049-53	2.9	40
35	Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007 , 17, 5989-94	2.9	38
34	Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004 , 14, 909-12	2.9	38
33	Farnesyltransferase inhibitors and anti-Ras therapy. <i>Breast Cancer Research and Treatment</i> , 1996 , 38, 75-83	4.4	37
32	Safety evaluation of 2'Fluoro-2'deoxy nucleotides in GalNAc-siRNA conjugates. <i>Nucleic Acids Research</i> , 2019 , 47, 3306-3320	20.1	35
31	Cellular distribution of cholesterol-linked, phosphoisoprenylated proteins in proliferating cells. <i>FEBS Letters</i> , 1989 , 245, 110-6	3.8	34
30	Endosomolytic bioreducible poly(amido amine disulfide) polymer conjugates for the in vivo systemic delivery of siRNA therapeutics. <i>Bioconjugate Chemistry</i> , 2013 , 24, 640-7	6.3	31
29	Development of 6-substituted indolylquinolinones as potent Chk1 kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006 , 16, 5907-12	2.9	31
28	Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 1447-65	5.9	30

27	Potent 2-[(pyrimidin-4-yl)amine]-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006 , 16, 1146-50	2.9	29
26	Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates. <i>Journal of Controlled Release</i> , 2014 , 183, 124-37	11.7	24
25	A novel orally bioavailable inhibitor of kinase insert domain-containing receptor induces antiangiogenic effects and prevents tumor growth in vivo. <i>Cancer Research</i> , 2004 , 64, 751-6	10.1	24
24	Cholesterol metabolism and tumor cell proliferation. <i>Sub-Cellular Biochemistry</i> , 1997 , 28, 363-435	5.5	23
23	Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007 , 17, 6280-5	2.9	21
22	Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 413-25	6.1	19
21	Novel endosomolytic poly(amido amine) polymer conjugates for systemic delivery of siRNA to hepatocytes in rodents and nonhuman primates. <i>Bioconjugate Chemistry</i> , 2014 , 25, 896-906	6.3	18
20	Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012 , 22, 2609-12	2.9	18
19	Growth inhibition by microRNAs that target the insulin receptor substrate-1. <i>Cell Cycle</i> , 2009 , 8, 2255-9	4.7	18
18	Cell-cycle-dependent, differential prenylation of proteins. <i>FEBS Journal</i> , 1991 , 200, 579-90		18
17	Regulation of microRNA-145 by growth arrest and differentiation. <i>Experimental Cell Research</i> , 2011 , 317, 488-95	4.2	16
16	Improving the in vivo therapeutic index of siRNA polymer conjugates through increasing pH responsiveness. <i>Bioconjugate Chemistry</i> , 2014 , 25, 296-307	6.3	15
15	A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 46, 79-83	3.5	13
14	An in vivo evaluation of amphiphilic, biodegradable peptide copolymers as siRNA delivery agents. <i>International Journal of Pharmaceutics</i> , 2014 , 466, 58-67	6.5	9
13	Expression of micro-RNA-145 is regulated by a highly conserved genomic sequence 3Tto the pre-miR. <i>Journal of Cellular Physiology</i> , 2011 , 226, 602-7	7	9
12	Isoprenylated proteins in myelin. <i>Journal of Neurochemistry</i> , 1994 , 62, 1539-45	6	9
11	Pyridyl aminothiazoles as potent Chk1 inhibitors: optimization of cellular activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012 , 22, 2613-9	2.9	8
10	Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling. <i>Journal of Molecular Graphics and Modelling</i> , 2004 , 23, 153-65	2.8	8

9	Development and implementation of multiplexed cell-based imaging assays. <i>Methods in Enzymology</i> , 2006 , 414, 284-300	1.7	7
8	Systematic chemical modifications of single stranded siRNAs significantly improved CTNNB1 mRNA silencing. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016 , 26, 4513-4517	2.9	6
7	Centyrin ligands for extrahepatic delivery of siRNA. <i>Molecular Therapy</i> , 2021 , 29, 2053-2066	11.7	6
6	Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 1300-11	7	5
5	A single dose of EGLN1 siRNA yields increased erythropoiesis in nonhuman primates. <i>Nucleic Acid Therapeutics</i> , 2014 , 24, 405-12	4.8	2
4	Comparison of flow and batch polymerization processes for production of vinyl ether terpolymers for use in the delivery of siRNA. <i>Journal of Polymer Science Part A</i> , 2014 , 52, 1119-1129	2.5	1
3	Immunohistochemical Detection of Antitumor, Antimetastasis, and Antiangiogenesis Effects of a Vascular Endothelial Growth Factor Receptor 2 Kinase Inhibitor in an Orthotopic Breast Cancer Metastasis Model. <i>Journal of Histotechnology</i> , 2010 , 33, 15-24	1.3	1
2	Pharmacokinetic/pharmacodynamic-based decision making in the development of MK-0888, a VEGFR-2/FLT-3 kinase inhibitor. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 333-42	3.5	
1	Prostate cancer: therapeutic patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2000 , 10, 1833-1842	6.8	